Skip to content
Screener

Denali Therapeutics Inc. DNLI Cumulative Cost Basis

Cumulative Cost Basis at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
——

Other financials

Income statement

See full
Revenue$3.6M—
Gross profit$3.5M—
Operating income-$130.5M+3.3%
Net income-$127.6M-2.8%
EPS (diluted)-$0.68+5.6%

Balance sheet

See full
Cash & equivalents$204.6M+41.8%
Total debt$37.7M-21.4%
Total equity$835.2M-18.7%
Total assets$1.2B-0.7%

Cash flow

See full
Operating cash flow-$97.0M-28.8%
CapEx$805.0K-81.2%
Free cash flow-$97.8M-22.9%

Valuation

See full
Market cap$3.92B+88.3%
Enterprise value$3.76B+89.0%
P/S1,089×+1,084×

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-54.9%+34.3pp
Debt / equity0×0.0×
Current ratio8.4×-1.9×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:08 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001714899-26-000097
Line itemAmortized CostUnrealized Holding GainsUnrealized Holding LossesAggregate Fair Value
U.S. government treasuries$409,364$20$(555)$408,829
Corporate debt securities100,34216(246)100,112
Total short-term marketable securities509,70636(801)508,941
Long-term marketable securities:
U.S. government treasuries164,059—(658)163,401
Corporate debt securities66,328—(195)66,133
Total long-term marketable securities230,387—(853)229,534
Total$740,093$36$(1,654)$738,475

Item 1. Financial Statements (Unaudited)

FAQ

What is Denali Therapeutics Inc.'s cumulative cost basis?
Denali Therapeutics Inc. (DNLI) reported cumulative cost basis of $509.71M in Q2 2026.
How has Denali Therapeutics Inc.'s cumulative cost basis changed year-over-year?
Denali Therapeutics Inc.'s cumulative cost basis decreased by 39.0% year-over-year, from $834.92M to $509.71M.
What is the long-term trend for Denali Therapeutics Inc.'s cumulative cost basis?
Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s cumulative cost basis has grown at a -7.8% compound annual growth rate (CAGR), from $995.15M to $661.61M.
What does cumulative cost basis mean?
The aggregate historical cost basis of assets or liabilities before adjustments for fair value, impairment, or amortization.

Ask your AI about Denali Therapeutics Inc.'s cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude